Board Change • May 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • May 16
ChemoMetec A/S, Annual General Meeting, Oct 08, 2026 ChemoMetec A/S, Annual General Meeting, Oct 08, 2026. Tillkännagivande • May 06
Chemometec A/S Upgrades Earnings Guidance for the Financial Year 2025/2026 ChemoMetec A/S upgraded earnings guidance for the financial year 2025/2026. For the year, the Company now expects revenue in the DKK 505 million - DKK 525 million range, up from DKK 490 million - DKK 520 million in the most recent guidance. To ensure continued compliance with the applicable accounting framework (IFRS), ChemoMetec has adjusted the allocation of revenue between instruments and services. Tillkännagivande • Mar 26
ChemoMetec A/S Revises Earnings Guidance for the Year 2025/2026 ChemoMetec A/S revised earnings guidance for the year 2025/2026. For the year, the company expects revenue of DKK 490 million to DKK 520 million is now expected in the financial year 2025/26 against the most recently announced DKK 565 million to DKK 580 million. Tillkännagivande • Feb 06
Chemometec A/S Maintains Earnings Guidance for the Year 2025 ChemoMetec A/S maintained earnings guidance for the year 2025. For the period, the company expects revenue in the range of DKK 565-580 million range. Tillkännagivande • Oct 28
ChemoMetec A/S Updates Earnings Guidance for the Year 2025-26 ChemoMetec A/S updated earnings guidance for the year 2025-26. For the year, the company now expects revenue to be DKK 565 million - DKK 580 million against the most recently announced DKK 545 million- DKK 565 million. The company expects a positive trend in revenue and profit particularly in the last part of the financial year 2025/26. Tillkännagivande • Oct 10
ChemoMetec A/S Approves to Distribute Dividend ChemoMetec A/S at the AGM held on 9 October 2025, approved to distribute a dividend of DKK 7 per share of a nominal value of DKK 1. Tillkännagivande • Sep 18
ChemoMetec A/S, Annual General Meeting, Oct 09, 2025 ChemoMetec A/S, Annual General Meeting, Oct 09, 2025, at 17:30 Romance Standard Time. Location: nordsjaellands konferencecenter, gydevang 39-41, 3450 allerod, Denmark Tillkännagivande • Jan 10
Chemometec A/S Updates Earnings Guidance for the 2024/2025 Financial Year ChemoMetec A/S updated earnings guidance for the 2024/2025 Financial year. For the year, company expected revenue in the DKK 470 million - DKK 490 million range, up from DKK 460 million - DKK 475 million in the most recent guidance. Tillkännagivande • Dec 04
ChemoMetec A/S Updates Earnings Guidance for the Financial Year 2024-2025 ChemoMetec A/S updated earnings guidance for the financial year 2024-2025. For the year, the company now expected revenue to be in the range of DKK 460 million to DKK 475 million, up from DKK 445 million to DKK 460 million in the most recent guidance. Recent Insider Transactions • Nov 13
Deputy Chairman & Senior Advisor recently bought €428k worth of stock On the 8th of November, Hans Glensbjerg bought around 7k shares on-market at roughly €61.17 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Hans has been a buyer over the last 12 months, purchasing a net total of €469k worth in shares. Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to €69.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €45.47 per share. Buy Or Sell Opportunity • Nov 12
Now 52% overvalued after recent price rise Over the last 90 days, the stock has risen 38% to €69.05. The fair value is estimated to be €45.47, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.2% over the last 3 years. Earnings per share has grown by 8.7%. For the next 3 years, revenue is forecast to grow by 14% per annum. Earnings are also forecast to grow by 17% per annum over the same time period. Tillkännagivande • Nov 08
ChemoMetec A/S Maintains Earnings Guidance for the Full-Year 2024-2025 ChemoMetec A/S maintained earnings guidance for the full-year 2024-2025. For the year, the company expects revenue to be in the range of DKK 445 million to DKK 460 million. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Chairman Niels Thestrup was the last director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment. Tillkännagivande • Oct 23
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA for €2.8 million on September 20, 2024. A cash consideration of €2.83 million will be paid by ChemoMetec A/S. As part of consideration, €2.83 million is paid towards common equity of Ovizio Imaging Systems NV/SA. For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
ChemoMetec now has three weeks to carry out a due diligence, and if the outcome of this is positive, ChemoMetec will most likely proceed with the acquisition. The transaction is subject to approval of offer by target shareholders, consummation of due diligence investigation and definitive agreement. The tender offer has already been accepted by shareholders owning more than two thirds of Ovizio, and ChemoMetec is currently in the process of obtaining acceptance from the remaining shareholders, who are under a legal obligation to accept. As of October 16, 2024, the deal has been approved by shareholders of Ovizio Imaging Systems NV/SA. Closing is expected to take place within the coming week and will coincide with the actual acquisition date.
ChemoMetec A/S (CPSE:CHEMM) completed the acquisition of Ovizio Imaging Systems NV/SA on October 22, 2024. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €58.40, the stock trades at a forward P/E ratio of 48x. Average forward P/E is 28x in the Life Sciences industry in Europe. Total loss to shareholders of 51% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.01 per share. Tillkännagivande • Oct 17
ChemoMetec A/S Revises Earnings Guidance for the Financial Year 2024/2025 ChemoMetec A/S revised earnings guidance for the financial year 2024/2025. The company sustained its positive performance in the first quarter of 2024/2025 with better-than-expected sales and order intake. Based on this, the company now expects revenue for the 2024/2025 financial year in the DKK 445 million to DKK 460 million range, up from DKK 435 million to DKK 450 million in the most recent guidance. Tillkännagivande • Oct 11
ChemoMetec A/S Approves Dividend ChemoMetec A/S at its Annual General Meeting held on 10 October 2024, approved the proposal of the Board of Directors to distribute a dividend of DKK 4 per share of a nominal value of DKK 1. Upcoming Dividend • Oct 04
Upcoming dividend of kr.4.00 per share Eligible shareholders must have bought the stock before 11 October 2024. Payment date: 15 October 2024. Payout ratio is a comfortable 51% but the company is paying out more than the cash it is generating. Trailing yield: 1.0%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (0.7%). Tillkännagivande • Sep 21
ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA. ChemoMetec A/S (CPSE:CHEMM) submitted an indicative offer to acquire Ovizio Imaging Systems NV/SA on September 20, 2024.
For the period ending December 31, 2023, Ovizio Imaging Systems NV/SA reported total revenue of €1.4 million.
The transaction is subject to consummation of due diligence investigation. Declared Dividend • Sep 15
Dividend of kr.4.00 announced Shareholders will receive a dividend of kr.4.00. Ex-date: 11th October 2024 Payment date: 15th October 2024 Dividend yield will be 7.2%, which is higher than the industry average of 0.5%. Sustainability & Growth Dividend is covered by earnings (73% earnings payout ratio) but not covered by cash flows (122% cash payout ratio). The dividend has decreased over the past 56 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 45% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Sep 12
Full year 2024 earnings released: EPS: kr.7.83 (vs kr.10.27 in FY 2023) Full year 2024 results: EPS: kr.7.83 (down from kr.10.27 in FY 2023). Revenue: kr.407.9m (down 8.2% from FY 2023). Net income: kr.136.3m (down 24% from FY 2023). Profit margin: 33% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Tillkännagivande • Sep 12
ChemoMetec A/S provides earnings guidance for the year 2024/25 ChemoMetec A/S provided earnings guidance for the year 2024/25. For the period, the company expected revenue to be in the DKK 435 million to DKK 450 million range against DKK 407.4 million last year. Valuation Update With 7 Day Price Move • Jul 05
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €48.04, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 59% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €32.31 per share. Tillkännagivande • May 25
ChemoMetec A/S Announces CFO Changes The board of ChemoMetec A/S appointed Kim Nicolajsen as new CFO with effect from 1 July 2024. Kim Nicolajsen comes from a similar position as CFO in the family-owned company Rohde Nielsen. He is state-authorized public accountant and has previously worked for KPMG and EY. The board has also entered into an agreement with the company's current CFO Niels Høy Nielsen that he will resign from his position at the same time as Kim Nicolajsen takes over. The board would like to thank Niels Høy Nielsen for his contribution to ChemoMetec and for the good cooperation. CEO Martin Helbo Behrens and CFO Kim Nicolajsen will hereafter form the executive management of ChemoMetec. Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €47.66, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 22x in the Life Sciences industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.71 per share. Buy Or Sell Opportunity • Apr 17
Now 24% overvalued Over the last 90 days, the stock has fallen 16% to €41.12. The fair value is estimated to be €33.23, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 24%. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 20% in the next 2 years. Valuation Update With 7 Day Price Move • Apr 13
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to €40.56, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 55% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.06 per share. Tillkännagivande • Apr 13
ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 ChemoMetec A/S provided earnings guidance for the year 2023/24. For the period, the company expected revenue to be in the DKK 400 million - DKK 415 million range against previously announced DKK 400 million - DKK 435 million and thus still within the most recently announced range. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €60.55, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 26x in the Life Sciences industry in Europe. Total loss to shareholders of 17% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.73 per share. Tillkännagivande • Mar 13
ChemoMetec A/S Announces CEO Changes The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of March 13, 2024. The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of March 13, 2024. Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024. With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future. CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 32% After last week's 32% share price gain to €64.05, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 23x in the Life Sciences industry in Europe. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €34.40 per share. Reported Earnings • Feb 07
First half 2024 earnings released: EPS: kr.4.05 (vs kr.6.06 in 1H 2023) First half 2024 results: EPS: kr.4.05 (down from kr.6.06 in 1H 2023). Revenue: kr.199.8m (down 18% from 1H 2023). Net income: kr.70.6m (down 33% from 1H 2023). Profit margin: 35% (down from 43% in 1H 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 06
ChemoMetec A/S Maintains Earnings Guidance for the Year 2024 ChemoMetec A/S maintained earnings guidance for the year 2024. The company maintain full-year guidance for 2023/24 of revenue in the range of DKK 400 million - DKK 435 million and EBITDA in the range of DKK 200 million - DKK 220 million. Tillkännagivande • Dec 21
ChemoMetec A/S Announces Executive Changes ChemoMetec A/S announced that COO and deputy chairman of the board Martin Glensbjerg has decided to step down in ChemoMetec to pass the baton on to the next generation. From 1 February 2024 until the end of 2024, he will act as Senior Advisor with reference to CEO Rasmus Kofoed. Martin Glensbjerg continues as deputy chairman of the board. In his new role, Martin Glensbjerg will, among other things, participate in the update of ChemoMetec's strategy and also contribute to ensuring a successful anchoring and launch of the upcoming new products, including XcytoMatic 40 and XcytoMatic 30. At the same time, Martin Helbo Behrens, Deputy COO, is appointed COO, and Bo Melholt Nielsen, Physicist & Project Manager, Chief R&D Officer. Both Martin Helbo Behrens and Bo Melholt Nielsen have been employed at ChemoMetec for a number of years. Before joining as Deputy COO earlier this year, Martin Helbo Behrens was CFO and COO in ChemoMetec's American subsidiary and was part of Group Finance before that. Bo Melholt Nielsen has a strong academic and professional background in physics, especially quantum optics, and as project manager for the development of XcytoMatic 40 and XcytoMatic 30 he has been a significant driving force behind the development of the new generation of products. Martin Glensbjerg was one of three co-founders when ChemoMetec was established in 1997, and since then he has held a leading position in the company and has made a significant contribution to ensuring that ChemoMetec has achieved an attractive global market position. Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to €55.30, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €39.98 per share. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to €43.46, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 21% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €41.87 per share. Buying Opportunity • Oct 25
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 41%. The fair value is estimated to be €45.51, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 27% over the last 3 years. Earnings per share has grown by 37%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 13% per annum over the same time period. Valuation Update With 7 Day Price Move • Oct 12
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €45.84, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Life Sciences industry in Europe. Total loss to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €44.40 per share. Upcoming Dividend • Oct 06
Upcoming dividend of kr.6.00 per share at 1.8% yield Eligible shareholders must have bought the stock before 13 October 2023. Payment date: 17 October 2023. Trailing yield: 1.8%. Lower than top quartile of German dividend payers (5.0%). Higher than average of industry peers (0.9%). Reported Earnings • Sep 14
Full year 2023 earnings released: EPS: kr.10.27 (vs kr.9.16 in FY 2022) Full year 2023 results: EPS: kr.10.27 (up from kr.9.16 in FY 2022). Revenue: kr.444.4m (up 3.7% from FY 2022). Net income: kr.178.7m (up 12% from FY 2022). Profit margin: 40% (up from 37% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. New Risk • Aug 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (30% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (7.0% average weekly change). Tillkännagivande • May 10
ChemoMetec A/S Affirms Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S affirmed earnings guidance for the fiscal year 2022/2023. For the year, based on developments in the third quarter of 2022/23, guidance for financial year 2022/23, as announced in connection with the release of the interim report for 2022/23 on 8 February 2023, is maintained. Accordingly, revenue for 2022/23 is expected in the range of DKK 430 million - DKK 460 million. Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to €52.90, the stock trades at a trailing P/E ratio of 38.1x. Average trailing P/E is 36x in the Life Sciences industry in Europe. Total returns to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • Feb 15
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to €66.20, the stock trades at a trailing P/E ratio of 48.1x. Average trailing P/E is 45x in the Life Sciences industry in Europe. Total returns to shareholders of 76% over the past three years. Reported Earnings • Feb 10
First half 2023 earnings released: EPS: kr.6.06 (vs kr.4.90 in 1H 2022) First half 2023 results: EPS: kr.6.06 (up from kr.4.90 in 1H 2022). Revenue: kr.242.7m (up 16% from 1H 2022). Net income: kr.105.4m (up 24% from 1H 2022). Profit margin: 43% (up from 41% in 1H 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 40% per year. Tillkännagivande • Feb 09
ChemoMetec A/S Updates Earnings Guidance for the Fiscal Year 2022/2023 ChemoMetec A/S updated earnings guidance for the fiscal year 2022/2023. For the year, the company expected revenue of DKK 430 million - DKK 460 million, against the previous guidance of DKK 485 million-DKK 505 million. Valuation Update With 7 Day Price Move • Dec 21
Investor sentiment deteriorated over the past week After last week's 16% share price decline to €93.70, the stock trades at a trailing P/E ratio of 76.9x. Average trailing P/E is 42x in the Life Sciences industry in Europe. Total returns to shareholders of 267% over the past three years. Tillkännagivande • Dec 15
Chemometec A/S Announces Resignation of Steen Søndergaard as CEO Steen Søndergaard has announced that he wants to resign from his position as CEO of ChemoMetec A/S. It has been agreed that Steen Søndergaard remains in his position until a replacement has been found, however with resignation during the calendar year 2023 and possibly no later than 30 June 2023. The search for a new CEO has been initiated, and the Board of Directors expects to announce the name of the new CEO during the first quarter of 2023. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Tillkännagivande • Nov 08
ChemoMetec A/S Provides Earnings Guidance for the Financial Year 2022-23 ChemoMetec A/S provided earnings guidance for the financial year 2022-23. For the period, the company expects revenue to be in the range of DKK 485 million - DKK 505 million. Valuation Update With 7 Day Price Move • Sep 24
Investor sentiment deteriorated over the past week After last week's 15% share price decline to €79.50, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 31x in the Life Sciences industry in Europe. Total returns to shareholders of 343% over the past three years. Reported Earnings • Sep 17
Full year 2022 earnings released: EPS: kr.9.16 (vs kr.5.08 in FY 2021) Full year 2022 results: EPS: kr.9.16 (up from kr.5.08 in FY 2021). Revenue: kr.428.4m (up 52% from FY 2021). Net income: kr.159.5m (up 81% from FY 2021). Profit margin: 37% (up from 31% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Tillkännagivande • Sep 15
ChemoMetec A/S Provides Revenue Guidance for the Fiscal Year 2023 ChemoMetec A/S provided revenue guidance for the fiscal year 2023. For the period, the company expects revenue in the range of DKK 485 million - DKK 505 million. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. 1 independent director (4 non-independent directors). Independent Director Peter Reich was the last independent director to join the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Feb 10
First half 2022 earnings: Revenues and EPS in line with analyst expectations First half 2022 results: EPS: kr.4.90 (up from kr.2.43 in 1H 2021). Revenue: kr.209.8m (up 58% from 1H 2021). Net income: kr.85.2m (up 101% from 1H 2021). Profit margin: 41% (up from 32% in 1H 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Upcoming Dividend • Oct 08
Upcoming dividend of kr.4.00 per share Eligible shareholders must have bought the stock before 15 October 2021. Payment date: 19 October 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (0.4%). Reported Earnings • Sep 18
Full year 2021 earnings released: EPS kr.5.08 (vs kr.3.51 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: kr.281.1m (up 31% from FY 2020). Net income: kr.88.4m (up 49% from FY 2020). Profit margin: 31% (up from 28% in FY 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Feb 10
New 90-day high: €80.40 The company is up 48% from its price of €54.50 on 11 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 10.0% over the same period. Reported Earnings • Feb 07
First half 2021 earnings released: EPS kr.2.43 (vs kr.1.68 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: kr.133.0m (up 28% from 1H 2020). Net income: kr.42.3m (up 54% from 1H 2020). Profit margin: 32% (up from 27% in 1H 2020). The increase in margin was driven by higher revenue. Is New 90 Day High Low • Dec 31
New 90-day high: €76.60 The company is up 37% from its price of €55.90 on 02 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 2.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: €66.30 The company is up 23% from its price of €54.00 on 17 September 2020. The German market is up 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 01
New 90-day high: €60.70 The company is up 14% from its price of €53.10 on 02 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 1.0% over the same period. Reported Earnings • Sep 19
Full year earnings released - EPS €3.51 Over the last 12 months the company has reported total profits of kr.59.2m, up 41% from the prior year. Total revenue was kr.214.1m over the last 12 months, up 22% from the prior year. Profit margins were 28%, which is higher than the 24% margin from last year. The increase in margin was driven by higher revenue. Is New 90 Day High Low • Sep 18
New 90-day high: €54.00 The company is up 26% from its price of €42.70 on 19 June 2020. The German market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 19% over the same period. 
